Eudragit® S 100-Coated Lipid Nanoparticles for Oral RNA Delivery: Mechanistic Advances and Implications for mRNA-Based Assays

Study Background and Research Question

RNA-based therapeutics have achieved unprecedented clinical success in recent years, as exemplified by the use of lipid nanoparticles (LNPs) as delivery vehicles for siRNA (Onpattro) and mRNA vaccines against COVID-19. Despite these advances, the administration of LNP-formulated RNA is currently limited to injectable routes, largely due to the instability of naked or LNP-encapsulated RNA in the gastrointestinal (GI) environment. The reference study by Haque et al. addresses a central challenge in the field: can LNPs be engineered for oral delivery, withstanding GI degradation while enabling efficient RNA release and transfection in target tissues?

Key Innovation from the Reference Study

The study introduces a novel strategy employing Eudragit® S 100 (Eu), a pH-sensitive enteric polymer, to coat LNPs and shield their RNA cargo during GI transit. Eudragit® S 100 remains insoluble in acidic gastric conditions but dissolves at higher pH, such as in the intestine, providing targeted protection and release. This design leverages the polymer’s established use in oral drug delivery, adapting it to the unique requirements of RNA-loaded LNPs. The innovation lies in both the selection of the enteric polymer and the demonstration that Eu-coated LNPs (Eu-LNPs) can preserve RNA integrity and maintain transfection efficiency after passage through simulated GI conditions (Haque et al., 2025).

Methods and Experimental Design Insights

The research team formulated LNPs using DLin-MC3-DMA (an ionizable lipid), cholesterol, DMG-PEG, and DSPC at a molar ratio of 50:38.5:10:1.5. These LNPs were then coated with 1% Eudragit® S 100 solution via a nanoprecipitation method in the presence of 0.25% acetic acid. Dynamic light scattering (DLS) was employed to characterize particle size, revealing initial LNPs at ~120 nm and Eu-LNPs at ~4.5 μm, which decreased to ~191 nm at pH 8, simulating intestinal conditions.

RNA entrapment and stability were evaluated using Ribogreen assays and agarose gel retardation, while protective capacity was tested by exposing the formulations to simulated gastric fluid (SGF) containing pepsin, simulating the harsh acidic and enzymatic environment of the stomach. The transfection efficiency of both coated and uncoated LNPs was measured in HEK-293 cells using standard in vitro protocols, with attention to the impact of phosphate buffer (PB) pretreatment, which mimics physiological uncoating conditions.

Core Findings and Why They Matter

The primary findings of the study demonstrate that:

• Eu-LNPs effectively protect encapsulated RNA from acidic degradation and pepsin digestion in simulated gastric conditions, unlike uncoated LNPs, which rapidly lose their payload (reference study).
• Upon transition to neutral/basic pH (as in the intestine), Eu-LNPs shrink to ~191 nm, facilitating the release of LNPs capable of cellular uptake and endosomal escape.
• Phosphate buffer pretreatment significantly enhances transfection efficiency, suggesting that proper uncoating in physiologically relevant conditions is critical for RNA release and biological activity.
• Eu-LNPs retain transfection capacity after sequential exposure to simulated gastric and intestinal fluids, a key requirement for oral RNA delivery platforms.

These results collectively underscore the potential of pH-responsive polymer coatings to bridge a critical gap in the oral administration of LNP-based RNA therapeutics, expanding the possible routes and applications of mRNA and siRNA technologies.

Comparison with Existing Internal Articles

Most existing internal resources, such as "Firefly Luciferase mRNA (ARCA, 5-moUTP): Stability, Mechanism, and Next-Generation Reporter Applications" and "Firefly Luciferase mRNA (ARCA, 5-moUTP): Stability, Delivery Mechanisms, and Advanced Applications", focus on the biochemical enhancements of reporter mRNAs—such as ARCA capping, 5-methoxyuridine modifications, and optimized poly(A) tails—that improve stability, translational efficiency, and immune evasion. These mechanisms address intracellular and systemic barriers to mRNA detection and expression, particularly in gene expression, cell viability, and in vivo imaging assays. However, while these articles discuss lipid nanoparticle delivery in the context of translational efficiency and immunogenicity, the specific challenge of oral delivery and GI-tract protection has been less explored.

The current reference study builds directly on the premise that highly stable, immune-evasive mRNA formulations—such as Firefly Luciferase mRNA (ARCA, 5-moUTP)—could achieve even broader utility if they can be reliably delivered via non-invasive oral routes. By coupling these advanced mRNA designs with Eu-coated LNP carriers, researchers could enable high-throughput screening of reporter activity in GI tissues and new models of oral gene therapy. In this sense, the reference paper extends the applicability of findings from internal articles to a previously inaccessible administration route.

Limitations and Transferability

While the study provides compelling preclinical evidence for the feasibility of oral LNP-mediated RNA delivery, several limitations merit consideration:

• Scale and in vivo validation: The experiments were conducted in vitro (HEK-293 cells) and with simulated gastric and intestinal fluids. Further in vivo studies are needed to confirm the pharmacokinetics, biodistribution, and therapeutic efficacy of orally delivered Eu-LNPs.
• Payload specificity: While the core findings are applicable to a variety of nucleic acid cargos, the formulation and release kinetics may vary with different RNA lengths and structures.
• Safety and regulatory considerations: Eudragit® polymers are widely used in oral drug delivery, but their long-term safety and potential immunogenicity in the context of repeated RNA administration require further investigation.
• Translational barriers: Efficient transcytosis across the intestinal epithelium remains a hurdle for systemic gene delivery; Eu-LNPs may be most immediately applicable for targeting GI tissues, unless further modified.

Protocol Parameters

• LNP composition: DLin-MC3-DMA: cholesterol: DMG-PEG: DSPC at a 50:38.5:10:1.5 molar ratio.
• Eudragit® S 100 coating: 1% (w/v) Eu in 0.25% acetic acid, applied via nanoprecipitation.
• Simulated gastric fluid (SGF) exposure: 30–60 min at pH ~1.2 with pepsin, to test stability.
• Simulated intestinal fluid exposure: Incubation at pH 8 to mimic enteric dissolution and payload release.
• Transfection efficiency assessment: Use HEK-293 cells and measure reporter expression after PB (phosphate buffer) pretreatment to simulate in vivo uncoating.
• Practical workflow tip: For reporter assays, select mRNA constructs with enhanced stability (e.g., 5-methoxyuridine, ARCA cap) to maximize signal post-delivery.

Why this cross-domain matters, maturity, and limitations

The successful adaptation of enteric polymer coatings for LNPs represents a significant step toward translating injectable RNA therapeutics into orally administered forms. This cross-domain advance is especially relevant for researchers aiming to study gene expression or therapeutic intervention in GI tissues, or to improve patient compliance. However, as the reference study cautions, full translation to systemic therapies will require additional engineering to overcome epithelial barriers and validate biodistribution in vivo. The field is at an early preclinical maturity for oral LNP-mRNA delivery.

Research Support Resources

For researchers looking to replicate or extend these protocols in reporter assays, Firefly Luciferase mRNA (ARCA, 5-moUTP) (SKU R1012) is a well-characterized, ARCA-capped and 5-methoxyuridine-modified mRNA suitable for encapsulation in LNPs and subsequent detection via bioluminescence. This reagent can streamline gene expression, cell viability, and in vivo imaging assays, particularly when robust signal and stability are required after oral or parenteral delivery. Detailed workflows and mechanistic insights are further discussed in related internal articles, including mechanistic deep-dives and real-world assay scenarios. APExBIO’s product portfolio supports a range of experimental needs in this evolving domain.